Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy

Xin Gao,1,* Yun Luo,1,* Yuanyuan Wang,1,* Jun Pang,1 Chengde Liao,2 Hanlun Lu,3 Youqiang Fang1
1Department of Urology, The Third Affiliated Hospital, Sun Yat-Sen University, 2Department of Radiology, The Second Affiliated Hospital, Sun Yat-Sen University, 3Materials Science Institute of Zhongshan University, Guangzhou, China

*These authors contributed equally to this work

Background: We designed dual-functional nanoparticles for in vivo application using a modified electrostatic and covalent layer-by-layer assembly strategy to address the challenge of assessment and treatment of hormone-refractory prostate cancer.

Methods: Core-shell nanoparticles were formulated by integrating three distinct functional components, ie, a core constituted by poly(D,L-lactic-co-glycolic acid), docetaxel, and hydrophobic superparamagnetic iron oxide nanocrystals (SPIONs), a multilayer shell formed by poly(allylamine hydrochloride) and two different sized poly(ethylene glycol) molecules, and a single-chain prostate stem cell antigen antibody conjugated to the nanoparticle surface for targeted delivery.

Results: Drug release profiles indicated that the dual-function nanoparticles had a sustained release pattern over 764 hours, and SPIONs could facilitate the controlled release of the drug in vitro. The nanoparticles showed increased antitumor efficiency and enhanced magnetic resonance imaging in vitro through targeted delivery of docetaxel and SPIONs to PC3M cells. Moreover, in nude mice bearing PC3M xenografts, the nanoparticles provided MRI negative contrast enhancement, as well as halting and even reversing tumor growth during the 76-day study duration, and without significant systemic toxicity. The lifespan of the mice treated with these targeted dual-function nanoparticles was significantly increased (Chi-square = 22.514, P < 0.0001).

Conclusion: This dual-function nanomedical platform may be a promising candidate for tumor imaging and targeted delivery of chemotherapeutic agents in vivo.

Keywords: nanoparticle, prostate cancer, targeting, chemotherapy, imaging

Introduction
Although substantial improvement has been made in the diagnosis and treatment of prostate cancer, the prognosis remains poor for patients who suffer from hormone-refractory prostate cancer.1 Currently, the treatment of hormone-refractory prostate cancer relies mainly on docetaxel-based chemotherapy. However, the application of docetaxel is compromised by its hydrophobic nature, nonselective toxicity, and propensity to induce multidrug resistance.2 Moreover, it is difficult to determine the effects of cancer therapy owing to the lack of specific and sensitive assessment modalities in clinical practice.3 Promisingly, multifunctional nanomedical platforms, by incorporating different capabilities and targeting strategies, are demonstrating potential sophistication,4,5 and greatly improving cancer diagnosis and therapeutic efficacy.6,7 However, an ongoing challenge is that multifunctional nanoparticles for in vivo application are required to be stable in the circulation, to be stealthy to evade
clearance by the reticuloendothelial system, and to have reactive groups on their surface for efficient conjugation of specific targeting ligands. Furthermore, penetration of the nanoparticles into cancer tissue that is distal from the blood vessels in vivo is influenced by the affinity and specificity of targeting ligands. Labeled with the appropriate antibodies to tumor membrane antigens, nanoparticles offer great specificity and sensitivity. One potential candidate, over-expressed in both local and metastatic prostate cancer, is prostate stem cell antigen. In contrast with other prostate cancer-associated tumor antigens, prostate stem cell antigen has been recognized as a truly prostate-specific membrane-bound protein, which participates in membrane recycling and becomes internalized by ligand-induced endocytosis. In this study, we engineered a dual-function nanoparticle-based system for in vivo application using an electrostatic and covalent layer-by-layer assembly strategy. Our formulations were characterized by a core-shell structure with a hydrophobic core providing a natural carrier environment for hydrophobic imaging and chemotherapeutic agents, and a multilayer shell endowing the particle with high aqueous dispersity, antibiofouling properties, and stability in vivo.

In addition, poly(D,L-lactic-co-glycolic acid) (PLGA) has been approved by the US Food and Drug Administration for clinical use, and superparamagnetic iron oxide nanocrystals (SPIONs) could be degraded to become incorporated into the hemoglobin pool in vivo, which may facilitate the translation of our vehicles into clinical practice. A surface-localized scAb antibody provided targeted delivery to prostate stem cell antigen-positive cancer cells with high selectivity and binding affinity, but had a smaller size than an intact antibody. The efficacy of dual-function nanoparticles and their targeting capability were assessed in vitro and in vivo.

Materials and methods

Materials

Carboxyl-modified poly(D,L-lactic-co-glycolic acid) (PLGA–COOH, 50:50, Resomer®, 34 kDa) was purchased from Absorbable Polymers International (Pelham, AL). Heterofunctional poly(ethylene glycol) (PEG) terminated by carboxylic acid and maleimide (mal-PEG–COOH, 3.4 kDa) and carboxyl terminal groups of methoxy(polyethylene glycol) (mPEG–COOH, 2 kDa) were obtained from Peking Jenkem Technology Co, Ltd (Beijing, China). Docetaxel, poly(allylamine hydrochloride) (PAH), and the other chemicals were purchased from Sigma-Aldrich (St Louis, MO). The mouse monoclonal antibody against prostate stem cell antigen and phycoerythrin (PE)-labeled goat antimouse IgG were obtained from Santa Cruz Biotechnology Inc (Santa Cruz, CA). PC3M and HT29 cells were ordered from the American Type Culture Collection (Manassas, VA). Cell culture medium and fetal bovine serum were purchased from Invitrogen Corporation (Carlsbad, CA). Hydrophobic SPIONs (6 nm) were synthesized using a previously described method.

Preparation of scAb-PLGA-SPIO/docetaxel nanoparticles

COOH-PLGA-SPIO/docetaxel nanoparticles

SPIO/docetaxel-PLGA-COOH nanoparticles were prepared using a single emulsion evaporation method with some modification. Briefly, hydrophobic SPION (2 mg/mL) and docetaxel (2 mg/mL) were dispersed in 2 mL of dichloromethane followed by addition of 20 mg of PLGA–COOH. The mixture was homogenized for 20 minutes to obtain a dispersion of SPION, PLGA, and docetaxel. The organic phase obtained was added to 10 mL of an aqueous solution containing 2% (w/v) polyvinyl alcohol and emulsified with a homogenizer for 5 minutes, and followed by 2 minutes of ultrasonication using a probe type sonicator over an ice bath. The emulsion was slowly dropped into 90 mL of 0.3% (w/v) polyvinyl alcohol solution and allowed to stir overnight in the fume hood to evaporate the organic solvent. The suspension was centrifuged at 1000 rpm to remove any larger aggregates. The nanoparticles were collected by centrifugal ultrafiltration, washed with deionized water, and resuspended for use.

H₂N-PLGA-SPIO/docetaxel nanoparticles

Amino-modified PLGA nanoparticles were prepared according to a previously reported method. In brief, 5 mg of COOH-PLGA-SPIO/docetaxel nanoparticles was dispersed in 20 mL of water and ultrasonicated for 5 minutes in an ice bath. Then, 20 µL of NH₃. H₂O (28–30 wt%) was added into the suspension to produce a weakly basic solution, 20 µL of aqueous PAH (10 mg/mL) was introduced, and the mixture suspension was ultrasonicated for 20 minutes in an ice bath. The PAH-modified PLGA nanoparticles were collected by magnetic field-guided accumulation, washed with water, and dispersed for subsequent experiments.

Synthesis of scAb-PEG₃₄₀₀-COOH

scAb-bearing free sulphydryl groups were prepared before conjugation with mal-PEG–COOH, as described by Chen et al. Next, 100 µL of ethylenediaminetetraacetic acid (EDTA) aqueous solution (0.5 M) was added into 500 µL of prostate stem cell antigen antibody in aqueous solution (0.2 µg/µL)
and incubated for 15 minutes at 4°C. 2-Mercaptoethylamine (300 mg) was dissolved in a mixture of 2.94 mL of phosphate-buffered solution and 60 μL of 0.5 M EDTA aqueous solution, and then mixed with the prostate stem cell antigen antibody solution. After incubation for 90 minutes at 37°C, the scAb solution obtained was purified three times with phosphate-buffered solution (pH 7.4, each 1 mL containing 20 μL of 0.5 M EDTA solution) by ultrafiltration (Amicon Ultra-4 centrifugal filter, regenerated cellulose membrane, molecular weight cutoff 10 kDa). Next, 100 μg of mal-PEG₃₄₀₀-COOH aqueous solution (dissolved in a mixture of 98 μL phosphate-buffered solution and 2 μL of 0.5 M EDTA solution) was mixed with the purified scAb solution and incubated overnight at 4°C. The scAb-functionalized PEG (scAb-PEG-COOH) was washed three times with phosphate-buffered solution (pH 7.4) using a Sepharose CL-4B column (GE Healthcare UK Limited, Buckinghamshire, UK) to remove the free mal-PEG-COOH.

scAb-PLGA-SPIO-docetaxel nanoparticles

scAb-PEG₃₄₀₀-COOH 84.7 μg was mixed with mPEG₂₀₀₀-COOH 81.8 μg in phosphate-buffered solution (pH 6.3) followed by addition of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) 500 μg and N-hydroxsuccinimide (NHS) 500 μg. After incubation for 20 minutes at room temperature, 1.72 mg of PAH-modified nanoparticles (H₂N-PLGA-SPIO/docetaxel) were added and incubated overnight at 4°C after homogenization. The scAb-PLGA-SPIO/docetaxel nanoparticles were purified using a centrifugal filter with a 100 kDa molecular weight cutoff (Millipore, MA). scAb-PLGA/docetaxel, PLGA/docetaxel, and scAb-PLGA-SPIO were prepared in a similar manner and used as a control. For imaging, PLGA-SPIO/coumarin and scAb-PLGA-SPIO/coumarin were synthesized using coumarin instead of docetaxel.

Determination of scAb on nanoparticle surface

The scAb on the nanoparticle surface was confirmed using flow cytometry, confocal laser scanning microscopy (CLSM) and protein assay. For flow cytometry, a dispersion of PLGA-SPIO/docetaxel or scAb-PLGA-SPIO/docetaxel was incubated with goat antimouse IgG-PE diluted with phosphate-buffered solution containing 0.9% bovine serum albumin for one hour at room temperature. The nanoparticles were purified by centrifugation, washed three times, resuspended, and introduced into a flow cytometer. The fluorescence intensity was analyzed using a FAC Scan flow cytometer (Becton Dickinson, Franklin Lakes, NJ) as described previously.²² scAb-PLGA-SPIO/docetaxel was directly analyzed as a blank control. For confocal microscopy, the scAb-PLGA-SPIO/coumarin was incubated with goat antimouse IgG-PE diluted with phosphate-buffered solution containing 0.9% bovine serum albumin for one hour, collected by centrifugation, washed, and resuspended before being imaged under a confocal microscope (LSM 510 Meta, Carl Zeiss, Jena, Germany). The amount of protein in the scAb-PLGA-SPIO/Dtxl was quantified using a bicinchoninic acid protein assay, as previously described.²²²³

Nanoparticle characterization

Particle size and transmission electron microscopy

The particle size distribution and zeta potential were determined using a ZetaPALS dynamic light-scattering detector (15 mW laser, incident beam 676 nm, Brookhaven Instruments, Holtsville, NY). The morphology of the nanoparticles was characterized using TEM with a JEOL JEM-200CX instrument at an acceleration voltage of 200 kV. A dispersion of nanoparticles was dropped onto a carbon-coated copper grid, dried in air at room temperature, and imaged within 24 hours.

Determination of SPIO and docetaxel content

The SPIO loading was quantified using a polarized Zeeman atomic absorption spectrophotometer (Model Z-2000 series). In brief, preweighed lyophilized nanoparticles were dispersed in 1 M aqueous solution of HCl to dissolve the SPIONs completely. The iron concentration was then determined by measuring the specific Fe absorption at around 248.3 nm and calibrated with Fe standard solutions. The SPIO-loading content was calculated as the ratio of iron oxide to the total weight of the nanoparticle sample. To determine the docetaxel content, 2 mL of acetonitrile was added to the same lyophilized sample for drug extraction. The sample was kept on a shaker rotating at 100 rpm for 48 hours at room temperature before addition of 4 mL of methanol. After centrifugation, the docetaxel content in the supernatant was measured by high-pressure liquid chromatography (Agilent 1100, Palo Alto, CA) equipped with a pentafluorophenyl column (Curosil-PFP, 250 × 4.6 mm, 5 μm, Phenomenex, Torrance, CA). Absorbance at 227 nm was measured to determine the docetaxel content using a previously established calibration. The dialysis method was used to monitor the release of docetaxel, as described previously.²

Phantom MRI

Dual-function nanoparticles (800 μL in phosphate-buffered solution) were dispersed in 200 μL of 2% (w/v) agar phosphate-buffered solution at a final concentration of
0–40 µg/mL Fe while warm and allowed to cool to room temperature. The prepared gels were positioned in a 1.5 T MR scanner (GE Healthcare UK Limited) at room temperature. To estimate the transverse relaxation time (T2), the images were acquired at different echo times with a repetition time of 5000 msec (spin echo T2-weighted imaging, field of view 150 mm × 150 mm, matrix 256 × 256, slice thickness 1.5 mm). The magnitude of the image intensities was measured within manually drawn regions of interest (ROI). T2 was obtained by fitting the data to a monoexponential decay curve using linearized least-squares optimization. T2 relaxivity (r2, s/µg mL) was calculated as the slope of relaxation rate (s, 1/T2) versus Fe concentration relationship.

In vitro cytotoxicity assay
Cytotoxicity was analyzed using the Cell Counting Kit-8 (CCK-8) assay according to the manufacturer’s protocol (Dojindo, Kumamoto, Japan). PC3M cells were seeded in 96-well plates at 2.5 × 10^4/well and allowed to undergo attachment. The cells were treated with docetaxel, PLGA/docetaxel, scAb-PLGA/docetaxel, PLGA-SPIO/docetaxel, scAb-PLGA-SPIO/docetaxel, and scAb-PLGA-SPIO at different concentrations for 24, 48, and 72 hours. Following treatment, the medium was replaced and no further dose of drug was added. After a further 4 days of incubation, 10 µL of CCK-8 solution was added. After incubation for 1–4 hours at 37°C, absorbance at 450 nm was measured using a microplate reader. IC50 values were quantitatively calculated by GraphPad Prism GraphPad Software (San Diego, CA) using nonlinear regression analysis.

Cellular uptake
Cellular uptake experiments were conducted as previously reported.24 In brief, PC3M cells were seeded in 6-well plates at 5 × 10^5 cells per well and allowed to attach for 24 hours. The medium was replaced with 2 mL of freshly prepared nanoparticle-containing medium (50 ng/mL docetaxel) and incubated for 2 hours. To examine the specificity of scAb-mediated uptake, PC3M cells were incubated with excess free prostate stem cell antigen monoclonal antibodies before incubation with scAb-PLGA-SPIO/docetaxel. The cells were washed six times, collected, and lysed in 100 µL of cell lysis buffer for 10 minutes. An aliquot was used for cell protein determination (bicinchoninic acid protein assay kit, Pierce, Rockford, IL). The docetaxel in the remaining portion was extracted by acetonitrile/methanol and then quantified by high-pressure liquid chromatography after centrifugation at 14,000 rpm for 10 minutes using a previously established calibration. The data were normalized to per milligram cell protein.

In vitro MRI scan
PC3M cells and HT29 cells were seeded into 60 mm plates at a density of 1 × 10^6 cells. After reaching 80% confluence, PC3M cells were incubated with PLGA-SPIO/docetaxel or scAb-PLGA-SPIO/docetaxel, and HT29 cells were incubated with scAb-PLGA-SPIO/docetaxel at an equivalent Fe concentration (15 µg/mL Fe). After incubation for one hour, the cells were washed, trypsinized, and collected by centrifugation. The cells were then fixed in 1% paraformaldehyde for one hour at 4°C and dispersed in 300 µL 0.4% (w/v) phosphate-buffered agar. The cells were scanned under a 1.5 T MR scanner, and the T2 value was determined as described in the MRI phantom. Untreated PC3M cells were used as a blank control.

Flow cytometry assay
PLGA-SPIO/coumarin and scAb-PLGA-SPIO/coumarin were used to perform the flow cytometry assay because of the fluorescence of coumarin. 1 × 10^6 cells of PC3M or HT29 were incubated with PLGA-SPIO/coumarin, scAb-PLGA-SPIO/coumarin, or void nanoparticles in culture medium at an equivalent concentration of coumarin (5 µg/mL) for 30 minutes at 37°C. The cells were then pelleted by centrifugation. Thereafter, the cells were washed immediately and analyzed using a flow cytometer (Becton Dickinson).

Confocal laser scanning microscopy
PC3M and HT29 cells were seeded in Bioptechs plates at 50,000 cells/plate and incubated overnight. The cells were rinsed twice with phosphate-buffered solution (pH 7.2) and preincubated at 37°C for one hour in serum-free medium. PLGA-SPIO/coumarin, scAb-PLGA-SPIO/coumarin, or void nanoparticles were added at an equivalent concentration of coumarin (5 µg/mL) and incubated for 2 hours at 37°C. The free nanoparticles were aspirated, and the cells were washed three times with phosphate-buffered solution and fixed with 4% paraformaldehyde solution for 20 minutes. Afterwards, the cells were counterstained for another 20 minutes with DAPI (1 mg/mL). The cells were imaged under a confocal microscope (LSM 510 Meta, Carl Zeiss, Gottingen, Germany). Fluorescence intensity was analyzed by Image J 1.43.

Xenograft preparation
All animal studies were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee at the University of Sun Yat-sen University.
Male BALB/c nude mice aged 6–8 weeks were purchased from Vital River Laboratories (Peking, China). To establish a xenograft, 3 × 10⁶ PC3M cells were suspended in 100 μL of phosphate-buffered solution and injected subcutaneously into the upper right flank.

**In vivo MRI**

scAb-PLGA-SPIO/docetaxel or PLGA-SPIO/docetaxel was injected through the tail vein at designated time points (5 mg Fe/kg per mouse). Afterwards, tumor-bearing mice were anesthetized with 1%–2.5% isoflurane (Abbott Laboratories, Abbott Park, IL) and placed in a 1.5 T MR scanner. T2-weighted images were acquired on a small animal MRI system using the following imaging parameters: spin-echo T2-weighted imaging, repetition time 1600 msec, echo time 80 msec, field of view 40 × 40, thickness 1 mm, NEX 1.0, and echo 1/1. The MRI signal intensity of tumor regions and leg muscles was measured within a defined ROI. Untreated tumor-bearing mice were used as a control.

**In vivo antitumor efficacy**

Tumor xenografts were allowed to reach approximately 300 mm³ before the mice received different treatments. Based on the previously reported maximal tolerated dose,14 tumor-bearing mice were treated by tail vein injection of phosphate-buffered solution, docetaxel (dissolved in dimethyl sulfoxide), scAb-PLGA-SPIO, PLGA-SPIO/docetaxel, or scAb-PLGA-SPIO/docetaxel five times every three days (total dose of 50 mg docetaxel/kg). Body weight and tumor size were also monitored every three days. The dimensions of the tumor were estimated in two perpendicular directions (length and width) using a caliper and the volumes were calculated by 0.5 × length × width². When the body weight loss persisted beyond 20% of the predosing weight or tumor volume exceeded 800 mm³, the mice were deemed to have reached the endpoint and were euthanized. At the endpoint, blood samples were collected from the orbital sinus, and white blood cell counts were then determined.

**Hematoxylin-eosin staining and immunohistochemical detection of apoptosis**

After each mouse was sacrificed, tumor tissues were immediately removed, fixed in 10% formalin, paraffin-embedded, and stained with hematoxylin-eosin using a standard clinical laboratory protocol. Terminal transferase uridyl nick-end labeling (TUNEL) staining was performed using a DeadEnd™ Colorimetric TUNEL system according to the manufacturer’s instructions (Promega, Madison, WI). In brief, after deparaffinization and antigen retrieval, the sections were incorporated with biotinylated nucleotide at the 3’-OH DNA ends using the recombinant terminal deoxynucleotidyl transferase (rTdT) enzyme and incubated for one hour at 37°C. Horseradish peroxidase-labeled streptavidin was bound to biotinylated nucleotides, and was detected using diaminobenzidine. Images were captured with an Olympus AX70 microscope (Olympus, Stockholm, Sweden).

**Statistical analysis**

The data were expressed as the mean ± standard deviation. Statistical significance was determined using the Student’s t-test or analysis of variance with Tukey’s test. P < 0.05 was considered to be statistically significant.

**Results and discussion**

**Dual-function nanoparticle formulation**

A schematic diagram of the nanoparticle formulation (scAb-PLGA-SPIO/docetaxel) is shown in Figure 1. The spherical, highly ordered SPIONs were hydrophobic owing to an oleic acid/oleylamine coating, which was essential for encapsulation. After SPIO and docetaxel were encapsulated into PLGA-COOH through an oil-in-water (o/w) emulsion and subsequent solvent evaporation,25 the nanoparticle surface was negatively charged as a result of the carboxy groups on the terminal of PLGA. The nanoparticles were then coated with a layer of positively charged PAH through electrostatic interaction,26 grafting active amino groups on the surface. Prostate stem cell antigen antibodies were pretreated with 2-mercaptoethylamine to yield scAb-bearing free sulfhydryl groups. To protect the biological activity of scAb, we initially conjugated scAb with the unstable maleimide group of mal-PEG₃₄₀₀-COOH in aqueous solution through a covalent interaction, as the major component, formed a “corona” around the core, and mal-PEG₃₄₀₀ as the functionalized component was conjugated with the targeting moiety. Most important, scAb-functionalized PEG₃₄₀₀ protruded from the PEG₃₄₀₀ corona for active tumor targeting due to its higher molecular weight. The density
of scAb on the nanoparticle surface could be optimized by varying the ratio of scAb-PEG$_{3400}$ to mPEG$_{2000}$. The targeting capability could be maximized by avoiding the unnecessary masking of scAb on the nanoparticle surface, which may compromise passive targeting. The nanoparticles synthesized were stable under physiological conditions, without noticeable aggregation (Figure S1).

**Determination of scAb on nanoparticle surface**

To determine the presence of scAb on the nanoparticle surface, we used PE-labeled secondary antibodies to recognize scAb. To avoid nonspecific recognition and absorption, we incubated the nanoparticles with secondary antibody solution containing 0.9% bovine serum albumin. As shown in Figure 2C, the blank control showed no red fluorescence, as determined by flow cytometry. In comparison with PLGA-SPIO/docetaxel (scAb-free nanoparticles), a substantial shift of PE fluorescence was demonstrated in scAb-PLGA-SPIO/docetaxel (scAb-conjugated nanoparticles), confirming the presence of scAb on the nanoparticle surface. Minor red fluorescence was also observed for PLGA-SPIO/docetaxel, which may be attributed to nonspecific adsorption of the secondary antibodies. Further, the results suggest that the targeted nanoparticles were almost conjugated with scAb. In order to visualize scAb on the nanoparticle surface by confocal laser scanning microscopy directly, coumarin was encapsulated into the nanoparticles instead of docetaxel as a probe. Unlike PLGA-SPIO/docetaxel (Figure 2B), scAb-PLGA-SPIO/docetaxel showed merged red/green fluorescence (Figure 2A), indicating that scAb was successfully conjugated with the nanoparticles, which agreed well with the results obtained by flow cytometry. It should be pointed out that the capacity of scAb to bind with secondary antibodies indicates that thiolation of antibodies may not affect their bioactivity. scAb conjugated with nanoparticles was quantified using the bicinchoninic acid protein assay, and was approximately 28.3 ± 6.7 µg per mg of scAb-PLGA-SPIO/docetaxel.

**Biophysicochemical characteristics and in vitro release behavior**

Dynamic light scattering provided information on the hydrodynamic particle size of whole clusters, and showed

---

**Figure 1** Synthetic scheme and preparation process for scAb-PLGA-SPIO/docetaxel using layer-by-layer strategy.

**Abbreviations:** PEG, poly(ethylene glycol); EDC, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; NHS, N-hydroxysuccinimide; PAH, poly(allylamine hydrochloride); PLGA, poly(D,L-lactic-co-glycolic acid); SPION, superparamagnetic iron oxide nanoparticles; Dtxl, docetaxel.

**Figure 2** Determination of scAb on the nanoparticle surface. Confocal microscopic images of coumarin(green)-loaded scAb-PLGA-SPIO/coumarin (A) and PLGA-SPIO/coumarin (B) incubated with PE(red)-labeled secondary antibodies. The merged fluorescence indicated by the arrows demonstrates that scAb was successfully conjugated to the nanoparticle surface. (C) A significant shift of PE fluorescence intensity could be observed for scAb-PLGA-SPIO/docetaxel (scAb-NPs) in comparison with blank control and PLGA-SPIO/docetaxel NPs, indicating the presence of scAb on the nanoparticle surface.

**Abbreviations:** NPs, nanoparticles; PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide; PE, phycoerythrin.
that the diameter of scAb-PLGA-SPIO/docetaxel was 187.4 ± 32.7 nm in phosphate-buffered solution (Figure 3A). The morphology of scAb-PLGA-SPIO/docetaxel was examined by TEM (Figure 3B). TEM observation provided evidence of successful encapsulation of clustered SPIO into the PLGA core, which could result in $T_1$ increased $T_2$ relaxation compared with individual SPIO. Docetaxel and SPIO were simultaneously encapsulated into scAb-PLGA-SPIO/docetaxel at 4.9% ± 1.69% w/w and 5.41% ± 1.23% w/w, respectively. The in vitro drug release profiles are shown in Figure 3E. An initial burst of 24.2% and 41.1% accumulative release was observed in the first 48 hours for scAb-PLGA-SPIO/docetaxel and scAb-PLGA/docetaxel, respectively, followed by sustained release. Cumulative release over the 764-hour period was 75.9% and 83% for scAb-PLGA-SPIO/docetaxel and scAb-PLGA/docetaxel, respectively. The initial release could be because of diffusion of docetaxel from the hydrophobic core due to the difference in concentration gradient with the outside environment, whereas the slow, diffusion-controlled process possibly depended on the rate of polymer biodegradation. scAb-PLGA-SPIO/docetaxel demonstrated a significantly slower drug release profile than did scAb-PLGA/docetaxel, indicating that introduction of hydrophobic SPIO into the system may facilitate controlled release of the drug. This may be understandable because docetaxel can partition into the oleic acid/oleylamine coating of SPIO to promote drug retention further in the core.

This sustained release pattern that allows for the presence of docetaxel within the tumor over an extended period is a prerequisite for preventing drug resistance and improving therapeutic efficacy. The release of SPIO was not detectable within 764 hours.

**MRI phantom**

The effect of scAb-PLGA-SPIO/docetaxel on $T_2$ shortening was caused by the large susceptibility difference between the magnetic nanocrystals and surrounding medium, resulting in microscopic magnetic field inhomogeneity in the presence of an externally applied magnetic field. $T_2$ relaxation ($r_2$) was generally used to evaluate the sensitivity of contrast-enhancing properties, and was determined from the slope of the linear fit of $1/T_2$ versus Fe concentration. Our results demonstrate that the magnetism of scAb-PLGA-SPIO/docetaxel was readily detectable by MRI (Figure 3C), and the MRI signal intensity decreased with the increase in scAb-PLGA-SPIO/docetaxel concentration. As expected, the relaxation rate $R_2$ ($R_2 = 1/T_2$) was linearly proportional to the Fe concentration within the analyzed concentration range (Figure 3D), and the $r_2$ of scAb-PLGA-SPIO/docetaxel was measured to be 2.07 s$^{-1}$ µg mL$^{-1}$.

**In vitro cytotoxicity and intracellular docetaxel concentration**

In vitro antitumor activity is shown in Figure 4A. Both docetaxel and the nanoparticles showed a sigmoidal dose-dependent cytotoxic effect on PC3M cells, as previously described. Longer incubation or increased concentration led to an overall decrease in cell viability. The scAb-conjugated nanoparticles showed a significantly antiproliferative advantage over scAb-free nanoparticles. The $IC_{50}$ values of scAb-PLGA-SPIO/docetaxel were 1.38-fold, 1.68-fold, and 1.95-fold lower than those for PLGA-SPIO/docetaxel at 24, 48, and 72 hours, respectively. In contrast, the $IC_{50}$ of scAb-PLGA-SPIO/docetaxel showed no significant difference compared with that of PLGA-SPIO/docetaxel in HT29 cells (Figure S2). Relative to the free drug, scAb-PLGA-SPIO/docetaxel showed approximately the same cytotoxic effect as docetaxel at 24 hours, but higher antitumor potential at 48 and 72 hours. A possible explanation can be proposed for the enhanced efficacy of nanoparticles relative to free drug even though only a portion of drug loaded in nanoparticles was released during the period that the drug-loaded polymeric nanoparticles were believed to circumvent the multidrug resistance effect derived from expression of the P-glycoprotein pump. Wang et al demonstrated that the...
increased antiproliferative effect of targeted nanoparticles in K562 leukemia cells was caused by competitive binding of nanoparticles to P-glycoprotein and resulting decrease in drug efflux. However, the exact mechanism needs to be investigated further. scAb-PLGA-SPIO was used as a control and showed no significant effect on inhibition of growth, indicating that docetaxel encapsulated into nanoparticles was the true source of cytotoxicity.

To investigate the possible mechanism of higher cytotoxicity of scAb-PLGA-SPIO/docetaxel than its counterpart, the level of intracellular docetaxel and a competitive binding assay were investigated. As shown in Figure 4B, scAb-PLGA-SPIO/docetaxel showed a 1.52-fold higher level of intracellular docetaxel than PLGA-SPIO/docetaxel in PC3M cells after 2 hours of incubation. However, the cellular uptake of scAb-PLGA-SPIO/docetaxel was significantly inhibited in the presence of the saturated amount of free antibodies in the medium, and the level of intracellular docetaxel was reduced to 40.6%. These results suggest that the higher cytotoxicity of scAb-PLGA-SPIO/docetaxel in PC3M cells could be due to the higher intracellular level of docetaxel. Intracellular docetaxel may originate from the cellular uptake of nanoparticles and/or the release of docetaxel into the medium and subsequent cellular uptake during incubation before the wash step. Because the in vitro release profile of scAb-PLGA-SPIO/docetaxel was identical to that of PLGA-SPIO/docetaxel (Figure S3), the higher level of intracellular docetaxel is likely to be attributable to the enhanced uptake of scAb-PLGA-SPIO/docetaxel via receptor-mediated endocytosis.
In vitro nanoparticle binding and internalization assay

The binding and internalization of targeting and nontargeting nanoparticles were investigated by flow cytometric analysis and CLSM in two cell lines with different prostate stem cell antigen expression levels. PC3M cells (prostate stem cell antigen-positive) and HT29 cells (prostate stem cell antigen-negative) were used as a model with different levels of prostate stem cell antigen expression (Figure S4). As shown in Figure 4C and D, a significant increase in fluorescence intensity was observed for scAb-PLGA-SPIO/coumarin compared with PLGA-SPIO/coumarin after 0.5 hours of incubation in PC3M cells (Figure 4D). In contrast, HT29 cells incubated with scAb-PLGA-SPIO/coumarin showed no significant difference in fluorescence intensity compared with PLGA-SPIO/coumarin. Meanwhile, the PC3M cells incubated with scAb-PLGA-SPIO/coumarin showed the highest fluorescence intensity, while PC3M cells incubated with PLGA-SPIO/coumarin exhibited similar fluorescence intensity relative to HT29 cells incubated with scAb-PLGA-SPIO/coumarin or PLGA-SPIO/coumarin. These results suggest that scAb-PLGA-SPIO/coumarin possesses potent binding affinity for prostate stem cell antigen-overexpressing PC3M cells.

Visible evidence of the targeted internalization of nanoparticles in cancer cells were obtained by CLSM. As shown in Figure 5A and B, the fluorescence intensity of scAb-PLGA-SPIO/coumarin was 2.12-fold higher than PLGA-SPIO/coumarin in PC3M cells after 2 hours of incubation. In contrast, scAb-PLGA-SPIO/coumarin showed no significantly increased accumulation in HT29 cells compared with PLGA-SPIO/coumarin. Although a little portion of coumarin could be released from the nanoparticles during the incubation period, most of the coumarin remained within the nanoparticles and was taken up into the cells as particles. Because the in vitro release profile of scAb-PLGA-SPIO/coumarin showed a negligible difference from that of PLGA-SPIO/coumarin, the increased fluorescence intensity may

**Figure 5** (A) Confocal laser scanning microscopy of PC3M cells (prostate stem cell antigen-positive) and HT29 cells (prostate stem cell antigen-negative) after 2 hours of incubation with void nanoparticles (control), PLGA-SPIO/coumarin, and scAb-PLGA-SPIO/coumarin, respectively. (B) Mean fluorescence intensity of PC3M and HT29 cells in Figure 5A. (C) In vitro T2-weighted images (cross section and sagittal section) of untreated PC3M cells, PC3M cells incubated with scAb-PLGA-SPIO/docetaxel or PLGA-SPIO/docetaxel, and HT29 cells incubated with scAb-PLGA-SPIO/docetaxel. (D) T2 values of PC3M and HT29 cells described in Figure 5C.

**Notes:** The results are shown as the mean ± standard error of the mean (n = 3). *P < 0.05.

**Abbreviations:** Dox, docetaxel; PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide; NPs, nanoparticles.
have been caused by the targeted delivery of scAb-PLGA-SPIO/coumarin to PC3M cells. These data are in agreement with the results obtained in the flow cytometric analysis and indicate that targeted nanoparticles are able to bind to PC3M cells effectively and become internalized by PC3M cells.

Because MRI can image at the cell level, taking advantage of excellent sensitivity and spatial resolution,21 we conducted MRI scanning to investigate the scAb-targeting specificity and cell-labeling efficiency of targeted nanoparticles. Enhancement of the effective uptake of SPION-loaded nanoparticles resulted in a significant darkening of the T₂-weighted MR images, with loss of MR signal intensity. As shown in Figure 5C, a decrease in MRI signal intensity was observed for scAb-PLGA-SPIO/docetaxel when compared with PLGA-SPIO/docetaxel in PC3M cells, and PC3M cells incubated with scAb-PLGA-SPIO/docetaxel showed a significant negative contrast enhancement relative to HT29 cells incubated with scAb-PLGA-SPIO/docetaxel. The high-magnification images after cell uptake of scAb-PLGA-SPIO/docetaxel revealed that SPION maintained their original morphology inside the cells for a period of time. Furthermore, T₂ was used to evaluate the function of MRI visibility quantitatively (Figure 5D). The untreated PC3M cells were used as a control and had a T₂ of 225.3 ± 25.3 msec, whereas all the T₂ values decreased when the cells were incubated with SPION-loaded nanoparticles. PC3M cells treated with scAb-PLGA-SPIO/docetaxel had a lower T₂ value in comparison with PC3M cells treated with PLGA-SPIO/docetaxel or HT29 cells treated with scAb-PLGA-SPIO/docetaxel (55.9 ± 10.6 msec versus 85.4 ± 11.2 msec or 92.4 ± 13.4 msec, P < 0.05). These results confirm the targeted uptake of scAb-PLGA-SPIO/docetaxel by prostate stem cell antigen-overexpressing cancer cells, but not by cancer cells that express a low level of prostate stem cell antigen.

**In vivo MRI**

Generally, the signal intensity of MR images is a function of the number of SPION-loaded nanoparticles in the tumor region. The efficacy of scAb-PLGA-SPIO/docetaxel in specifically targeting PC3M cells and providing MRI negative contrast enhancement in vivo was evaluated in male nude mice bearing PC3M xenografts. The T₂-weighted MR images were acquired prior to injection and at various intervals post-injection to investigate nanoparticle accumulation to the tumor and define the optimal time window for achieving the maximal MRI contrast enhancement. MR signal intensity of tumors from untreated mice was defined at 100. As shown in Figure 6A, a negative contrast enhancement was observed in the tumors after intravenous administration, indicative of accumulation of a detectable amount of nanoparticles within the tumor, and up to maximum at 0.5 hours post-injection in both the PLGA-SPIO/docetaxel and scAb-PLGA-SPIO/docetaxel groups. Subsequently, the normalized MR signal intensity in the tumor regions increased from 57.1 ± 6.1 at 0.5 hours to 94.8 ± 3.3 at 36 hours for PLGA-SPIO/docetaxel and from 49.1 ± 4.5 at 0.5 hours to 82.6 ± 6.5 at 36 hours for scAb-PLGA-SPIO/docetaxel (Figure 6B). Meanwhile, we did not observe a significant change in the MR signal intensity of muscle tissue. The decrease of MR contrast enhancement in the tumor with increasing time may be attributed to nanoparticle sequestration within the reticuloendothelial system.23 Moreover, after cellular internalization, hydrolytic enzymes degraded intracellular SPION, and the nanoparticles consequently lost their capacity for contrast enhancement.15 It should be noted that cancer chemotherapy would proceed with intracellular docetaxel after degradation of SPION. The MR signal intensity for scAb-PLGA-SPIO/docetaxel at 0.5 hours post-injection showed no statistical advantage.
over PLGA-SPIO/docetaxel, but was lower than PLGA-SPIO/docetaxel at 4, 6, 12, 24, and 36 hours post-injection. This may be because scAb-PLGA-SPIO/docetaxel could be taken up by PC3M cells more specifically and efficiently than could PLGA-SPIO/docetaxel after accumulation in the tumor interstitium, resulting in a lower nanoparticle concentration in the tumor interstitium, more nanoparticles extravasating out of the vasculature, further facilitation of nanoparticle accumulation, and subsequently improved contrast enhancement of the tumor. However, after intravenous administration of nanoparticles, both scAb-PLGA-SPIO/docetaxel and PLGA-SPIO/docetaxel initially accumulated in the tumor interstitium via the enhanced permeability and retention effect, which was independent of the targeting moiety, possibly leading to a lack of significant difference in MRI signal intensity at 0.5 hours post-injection.

**In vivo antitumor efficacy and toxicity**

To examine the therapeutic efficacy of our nanoparticles, we randomly divided mice bearing established PC3M tumors into five groups to minimize any differences in weight and tumor size between the groups after tumors had developed to about 300 mm$^3$. As demonstrated in Figure 7A and B, no mice showed tumor regression in the phosphate-buffered solution. **Figure 7** scAb-PLGA-SPIO/docetaxel demonstrated a superior outcome in a PC3M xenograft animal model. (A) Volumes of PC3M carcinoma in different groups. (B) Representative PC3M tumors excised from different groups. (C) Kaplan–Meier survival curve demonstrates that scAb-PLGA-SPIO/docetaxel significantly increased the lifespan of the mice. (D) Hematoxylin-eosin staining and terminal transferase uridyl nick-end labeling (TUNEL) staining of excised median tumors at 100× magnification. Histological staining was evaluated by two independent pathologists. Nuclei with dark brown horseradish peroxidase staining indicates apoptosis. (E) Body weight of the nude mice in different groups. (F) Effect of different treatments on the white blood cell counts at the endpoint of observation. 

*Note:* The results are shown as the mean ± standard error of the mean (n = 5).

*Abbreviations:* Dtxl, docetaxel; PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide; PBS, phosphate-buffered solution.
solution group or scAb-PLGA-SPIO group. The mice in the docetaxel group experienced initial tumor regression, but exhibited subsequent progression, and all the mice in this group reached the endpoint during the observation period (Figure 7C). In contrast, scAb-PLGA-SPIO/docetaxel and PLGA-SPIO/docetaxel induced long-term tumor inhibition, and the mean tumor volume at the endpoint of observation was 156.4 ± 12.6 mm³ and 269.9 ± 225.4 mm³, respectively (Figure 7C). Notably, two mice in the scAb-PLGA-SPIO/docetaxel group experienced complete tumor regression. Furthermore, there was a significant increase in the lifespan of mice treated with scAb-PLGA-SPIO/docetaxel (Chi-square 22.514, P < 0.0001). The numbers of animals that survived in the scAb-PLGA-SPIO/docetaxel and PLGA-SPIO/docetaxel groups were four and two at the endpoint of observation, respectively (Figure 7C). Hematoxylin-eosin staining and detection of apoptosis were performed on excised representative tumors. As shown in Figure 7D, a significant ablation of tumor mass and the presence of fibrotic tissue were observed in representative tumors from the scAb-PLGA-SPIO/docetaxel group. A high level of apoptosis of tumor cells, as determined by TUNEL assay, was detected in tumor sections harvested from the mice treated with PLGA-SPIO/docetaxel and docetaxel, but not from the mice treated with scAb-PLGA-SPIO/docetaxel. This lack of apoptosis may have been due to the presence of significant fibrotic tissue instead of tumor mass in tissue from the scAb-PLGA-SPIO/docetaxel group compared with the other groups. These results demonstrate that scAb-PLGA-SPIO/docetaxel was more efficacious in tumor inhibition than the other treatments.

In vivo toxicity was assessed by analyzing the change in white blood cells and body weight loss, which are highly susceptible to cytotoxic agents. In the phosphate-buffered solution and scAb-PLGA-SPIO groups, the trend for body weight loss roughly paralleled the tumor load. The mice in the docetaxel, PLGA-SPIO/docetaxel, and scAb-PLGA-SPIO/docetaxel groups experienced an acute decrease in body weight, and showed a maximal mean body weight loss of 15.97% ± 1.91%, 13.96% ± 3.28%, and 8.28% ± 5.12%, respectively (Figure 7E). At the endpoint, white blood cells in all the groups were within the normal range (Figure 7F), suggesting no leukopenia or associated toxicity.

One possible explanation for the enhanced efficacy and reduced systemic toxicity of scAb-PLGA-SPIO/docetaxel compared with PLGA-SPIO/docetaxel in vivo may be that scAb-PLGA-SPIO/docetaxel was designed to bind specifically to prostate stem cell antigen on prostate cancer cells, possibly delaying nanoparticle clearance from the tumor site, increasing cellular uptake and facilitating intracellular delivery of docetaxel. Compared with scAb-PLGA-SPIO/docetaxel, more PLGA-SPIO/docetaxel may diffuse away from the tumor site or be phagocytosed by reticuloendothelial system cells, or prematurely release docetaxel in the other organs, leading to decreased efficacy and increased toxicity.

**Conclusion**

In summary, a dual-function polymer nanomedical platform was successfully developed to simultaneously provide effective prostate cancer cell-targeted MRI imaging and drug delivery, resulting in increased antitumor efficacy and MRI contrast enhancement. It is conceivable that the nanomedical platform could be easily extended to other cancers by switching the chemotherapeutic agent and targeting moiety. Thus, this targeting dual-function nanomedical platform could have potential value for drug delivery and tumor imaging in future nanomedicine.

**Acknowledgments**

The interdisciplinary collaboration and expert technical support of Wusheng Guo from the Department de Química of Universitat Autònoma de Barcelona is gratefully acknowledged. We also thank Minzhi Rong at the Materials Science Institute of Zhongshan University for valuable suggestions and critical reading of this manuscript. This work was supported by grants from the Chinese National Natural Science Foundation (30973011 to XG, 30901496 to JP), the 2010 Clinical Key Project of Ministry of Public Health, the Key Project of Guangdong Provincial Science and Technology Research (7117362 to XG), Medical Scientific Research Foundation of Guangdong Province of China (B2011097), Specialized Research Fund for the Doctoral Program of Higher Education of China (2011017120088), and Guangdong Science and Technology Project (2011B061200007).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Supplementary materials

Overexpression of prostate stem cell antigen on the surface of PC3M cells

Western blot and immunofluorescence were used to confirm overexpression of prostate stem cell antigen as a membrane-bound protein. PC3M and HT29 cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin 100 U/mL, and streptomycin 100 mg/mL under 5% CO<sub>2</sub> at 37°C. For immunofluorescence, PC3M cells were seeded in a 6-well plate at a density of 2 × 10<sup>5</sup> cells and allowed to reach approximately 80% confluence. The cells were blocked with goat serum for 30 minutes at room temperature and incubated overnight with mouse monoclonal prostate stem cell antigen antibody at 4°C. After being washed with phosphate-buffered solution, the cells were incubated with FITC-labeled goat antimouse secondary antibody for one hour. The cells were washed and further incubated for another 20 minutes after addition of the DNA-staining agent, DAPI (1 mg/mL). Images were obtained using a Zeiss Axiovert fluorescence microscope. Western blot analysis was conducted as previously described.<sup>1</sup> Labeled bands were detected by enhanced chemiluminescence plus (ECL-plus, Amersham, 300250200150100500).

![Graph showing hydrodynamic size distribution](image)

**Figure S1** Hydrodynamic size distribution graphs of scAb-PLGA-SPIO/docetaxel measured as a function of time upon incubation in PBS (closed squares) and RPMI containing 10% FBS.

**Note:** The results are shown as the mean ± standard error of the mean (n = 3).

**Abbreviations:** PBS, phosphate-buffered solution; FBS, fetal bovine serum; PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide.

![Graph showing IC<sub>50</sub> values](image)

**Figure S2** IC<sub>50</sub> in HT29 (prostate stem cell antigen-negative) cells after 24, 48, or 72 hours of incubation with PLGA-SPIO/docetaxel and scAb-PLGA-SPIO/docetaxel. scAb-PLGA-SPIO/docetaxel showed no significant difference from PLGA-SPIO/docetaxel in inhibiting the growth of HT29 cells.

**Notes:** The Cell Counting Kit-8 assay was used to evaluate cytotoxicity. The results are shown as the mean ± standard error of the mean (n = 3).

**Abbreviations:** PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide; Dtxl, docetaxel.

![Graph showing cumulative drug release](image)

**Figure S3** In vitro docetaxel release profiles of scAb-PLGA-SPIO/docetaxel and PLGA-SPIO/docetaxel. The in vitro release profile of scAb-PLGA-SPIO/docetaxel showed negligible difference from that of PLGA-SPIO/docetaxel.

**Abbreviations:** PLGA, poly(D,L-lactic-co-glycolic acid); SPIO, superparamagnetic iron oxide.

![Western blot and immunofluorescence images](image)

**Figure S4** (A) The level of prostate stem cell antigen expression in HT29 and PC3M cells as determined by Western blot analysis. (B) Immunofluorescence images indicate that PC3M cells express prostate stem cell antigen on the cell membrane (blue, nucleus; green, prostate stem cell antigen).
Amersham Pharmacia Biotech, Uppsala, Sweden). The bands were quantitated with the Bio-Rad VersaDoc image system (Hercules, CA). The HT29 cells were analyzed as a control.

Reference